DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
CleanMax Enviro plans Rs 5,000 cr IPO to boost renewable energy growth
21/05/2025
Indices decline over 1% amid Covid-19 surge and foreign inflow concerns
21/05/2025
Indian markets need a stronger macro environment : Ajay Rajadhyaksha, Barclays
21/05/2025
Strategic acquisition, expanding reach key to future growth of IPO-bound Belrise
20/05/2025
Fortis Healthcare Q4 Results : Net profit falls 7% to Rs 188 crore
20/05/2025
United Spirits Q4 results : Johnnie Walker maker reports 75% YoY jump in cons PAT to Rs 421 crore, declares Rs 8/share dividend
20/05/2025
